Related Experiment Video
Updated: Feb 22, 2026

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
Published on: July 27, 2022
Ventricular tachycardia after initiation of fingolimod
Farah Elounais1, Ahmed Aburahma1, Mohammad Luay Alkotob2
1Department of Internal Medicine, Hurley Medical Center, Flint, Michigan, USA.
Abstract:
Fingolimod, a sphingosine-1-phosphate receptor modulator, is used for the treatment of relapsing-remitting multiple sclerosis. It is well known to cause bradyarrhythmias. We present a 63-year-old woman who was admitted to the hospital with sustained monomorphic ventricular tachycardia 2 weeks after fingolimod initiation. Further evaluation showed that the patient's ventricular tachycardia was most likely secondary to her medication. Medical practitioners need to be aware of such possible life-threatening side effects while using fingolimod.
Related Concept Videos
Myocarditis III: Medical Management
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Myocarditis IV: Nursing Management
Myocarditis I: Introduction
Heart Failure Drugs: Inotropic Agents
Dysrhythmias III: Characteristics of Dysrhythmias

